1832 Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

1832 Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-440,145	Closed	-$175M	–	653
2025 Q4	$175M	Sell	440,145 -19,200	-4%	-$8.5M	0.13%	108
2025 Q3	$209M	Buy	459,345 +236,000	+106%	+$96.1M	0.17%	73
2025 Q2	$72.8M	Buy	223,345 +79,300	+55%	+$21.9M	0.06%	162
2025 Q1	$38.9M	Buy	+144,045	New	+$37M	0.04%	221
2024 Q3	–	Sell	-545	Closed	-$132K	–	680
2024 Q2	$132K	Hold	545	–	–	﹤0.01%	658
2024 Q1	$81.5K	Hold	545	–	–	﹤0.01%	676
2023 Q4	$104K	Hold	545	–	–	﹤0.01%	655
2023 Q3	$96.5K	Hold	545	–	–	﹤0.01%	668
2023 Q2	$104K	Sell	545 -22,200	-98%	-$4.4M	﹤0.01%	670
2023 Q1	$4.56M	Sell	22,745 -368,600	-94%	-$77.5M	0.01%	415
2022 Q4	$93M	Buy	391,345 +4,200	+1%	+$896K	0.15%	120
2022 Q3	$77.5M	Buy	387,145 +386,600	+70,936%	+$73.7M	0.14%	137
2022 Q2	$79K	Hold	545	–	–	﹤0.01%	724
2022 Q1	$88K	Buy	+545	New	+$83K	﹤0.01%	757
2020 Q2	–	Sell	-20,900	Closed	-$2.29M	–	645
2020 Q1	$2.29M	Buy	+20,900	New	+$2.41M	0.01%	388

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

1832 Asset Management's ALNY Position: Q1 2026 in Review

1832 Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 440,145 shares — an estimated $175M sold.

1832 Asset Management first reported a position in ALNY in Q1 2020 and held it in 15 quarters. The position peaked at $209M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

1832 Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
1832 Asset Management sold 440,145 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $175M.
1832 Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2020 and held it in 15 quarters.
1832 Asset Management's Alnylam Pharmaceuticals position peaked at $209M in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.